Publicaciones de prensa

Back to previous page

ReGen Biologics Reports Sales Progress and Provides Business Update

April 3, 2008

ReGen Biologics Reports Sales Progress and Provides Business Update

Hackensack, NJ – April 3, 2008 – ReGen Biologics (the “Company”) (OTC: RGBI) filed its 2007 Annual Report on Form 10-K on March 27.  It can be viewed in the Investor section of the Company’s website www.regenbio.com.

Highlights in the report include significant improvement in several key sales measures.  Annual revenue for 2007 increased 68% over the previous year to $986,000.  In the same time period Menaflex™ dollar sales increased 140% to $553,000 while Menaflex unit sales increased 94% to 352 units.

As of December 31, 2007 the Company had $4.1 million in cash and investment balances, representing approximately 6 to 7 months’ cash based upon the Company’s estimated 2008 burn rate.  The Company is evaluating its financing options.

The Company is continuing to pursue its appeal of the previously announced NSE decision received from the FDA regarding the Company’s collagen scaffold 510(k) filing.  Communications with the FDA are ongoing and the Company will provide further updates as additional information becomes available.

“Our marketing efforts last year resulted in notable progress, including sales gains and new distribution agreements for Poland and South Africa.  We continue to enter new markets, most recently launching the Menaflex collagen meniscus implant in the United Kingdom,” stated Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer.

Through its new product branding efforts and website www.menaflex.com, the Company believes that consumer demand will help to drive product awareness and connect patients with trained surgeons.  Based on increasing surgeon adoption, new market penetration, and increasing consumer awareness, the Company believes it is poised to at least double the ex-U.S. sales of its Menaflex product in 2008.

About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  ReGen’s first approved product using its collagen scaffold technology is the Menaflex™ meniscus application, which is cleared for sale in Europe and other countries and marketed through ReGen’s European subsidiary, ReGen Biologics AG. ReGen continues to work to obtain FDA clearance of the Menaflex device in the United States.

For more information on ReGen, visit www.regenbio.com .
 
Contact:

Brion Umidi    
ReGen Biologics, Inc.    
Chief Financial Officer    
(201) 651-3515    
bumidi@regenbio.com